Teva Pharmaceutical Industries ADR (TEVA)
$16.40
0.42 (2.50%)
TEVA Stock Quote Delayed 30 Minutes
Biotech Movers: A Tough Week All Around
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
18.21B
PE Ratio
-117.14
EPS
-0.14
Volume (Avg. Vol.)
6.55M
Day's Range
$16.32 - $16.73
52-Week Range
$7.46 - $17.69
Dividend & Yield
N/A (N/A)
TEVA Stock Predictions, Articles, and Teva Pharmaceutical Industries ADR News
4 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of four Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Swing for the Fences With These 5 Biotech Stocks
If you're prepared for the very high stakes and high risks of biotech investing, these five biotech stocks might be worth your while.
Investors Bag the Groceries: Thursday’s IP Market Recap
Markets were down as continued worries about Europe and another round of disappointing earnings and guidance pushed prices lower.
Brutal Day for Banks & Tech — Monday’s IP Market Recap
The broader markets were slammed by news across the Atlantic on Monday, with banks and tech stocks taking the brunt of it.
Watson Pharmaceuticals Is No Ordinary Generic
Watson Pharmaceuticals is an outstanding company that grows earnings and revenues every year in the tough generic pharma space. Consider this a top buy.
Got Nerve? Israel Has Plenty to Offer
A resilient economy and a focus on innovation are strong lures. And more Israel-based companies are listed on the Nasdaq than any other country except the U.S.
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance.
3 High-Yield Dividend Stocks to Avoid
Don't be tempted by the juicy payouts offered by these three well-known names. Those big dividends mask a lot of bigger problems.
2 Stocks to Watch for the Earnings Junkies
Canadian oil extractor Cenovus and international pharmaceutical company Teva announced positive earnings reports lately. See how they each stack up.
If Novartis’ MS Drug Falters, Biogen Will Gain
After the deaths of 11 people who were taking the drug, concerns that Gilenya may cause heart problems has hit NVS hard, ending the stock's months-long upswing.
Teva’s New CEO Is Battle-Tested. Good Thing
Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker.
3 Forgotten Stocks Worth Reconnecting With
These stocks are well off their recent highs, but because they've maintained quality fundamentals, they now present bargain opportunities.
10 Game-Changing Health Care Stocks to Buy
These 10 diverse stocks are likely to improve their earnings and stock prices in 2012. Take a look.
Investors Still Must Pick Generic Drug Companies By Hand
The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves.
Biogen Is in the Right Place at the Right Time
BIIB's promising multiple scerlosis drug BG-12 could be a huge winner, just when Novartis' entry is stumbling.
3 International Stocks to Hold Forever
Some of the best stocks to buy and hold forever are companies that sell things we'll want forever. Here are three that do so from overseas.
7 Pharma Stocks to Sell, STAT
Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss.
Shortage of Cancer Drugs Jeopardizes Development of New Treatments
Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.
